

LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claim 1. (Currently Amended) The compound 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-[[(-)] 7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate.

Claim 2. (Previously Presented) The compound of claim 1, wherein the 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form (α) exhibiting an X-ray powder diffraction pattern having characteristic reflexes (expressed in degrees of diffraction angle 2θ) at approximately: 9.0, 10.0, 12.8, 15.9, 18.1, 18.8, 19.8, 20.1, 21.8, 23.7.

Claim 3. (Previously Presented) The compound of claim 1, wherein the 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form (α), characterized by an X-ray powder diffraction pattern shown in FIG. 1.

Claim 4. (Previously Presented) The compound of claim 1, wherein the 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form (α), exhibiting an infrared spectrum recorded in attenuated total reflectance having characteristic absorption bands expressed in reciprocal centimeters at approximately: 3246, 1644, 1455, 1381, 1368, 1292, 1117, 1092, 1042, 743.

Claim 5. (Previously Presented) The compound of claim 1, wherein the 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form (α), characterized by a complete infrared spectrum shown in FIG. 2.

Claim 6. (Previously Presented) The compound of claim 1, wherein the 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form (α), exhibiting a melting point at approximately 248° C.

Claim 7. (Previously Presented) The compound of claim 1, wherein the 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form (α), characterized by a complete differential scanning calorimeter trace shown in FIG. 3.

Claim 8. (Previously Presented) The compound of claim 1, wherein the 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form (β), exhibiting an X-ray powder diffraction pattern having characteristic reflexes (expressed in degrees of diffraction angle 2θ) at approximately: 9.3, 11.6, 12.2, 17.6, 18.0, 18.6, 19.3, 20.8, 23.4, 26.5.

Claim 9. (Previously Presented) The compound of claim 1, wherein the 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form (β), characterized by an X-ray powder diffraction pattern shown in FIG. 4.

Claim 10. (Previously Presented) The compound of claim 1, wherein the 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form (β), exhibiting an infrared spectrum recorded in attenuated total reflectance having characteristic absorption bands expressed in reciprocal centimeters at approximately: 3338, 3279, 1602, 1564, 1389, 1219, 1154, 1134, 1034, 732.

Claim 11. (Previously Presented) The compound of claim 1, wherein the 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form (β), characterized by a complete infrared spectrum shown in FIG. 5.

Claim 12. (Previously Presented) The compound of claim 1, wherein the 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form (β), exhibiting a melting point at approximately 220° C.

Claim 13. (Previously Presented) The compound of claim 1, wherein the 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form (β), characterized by a complete differential scanning calorimeter trace shown in FIG. 6.

Claim 14. (Currently Amended) A composition comprising at least one compound from any one of claims 1-13 and a pharmaceutically acceptable carrier.

Claim 15. (Original) The composition of claim 14, comprising an effective amount of 4-(4-trans-hydroxy-cyclohexyl)amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate.

Claim 16. (Original) The composition of claim 15, in a parenteral dosage form.

Claim 17. (Currently Amended) A method for the treatment of a condition selected from the group consisting of essential hypertension, congestive heart failure and renal failure, comprising administering an effective amount of at least one compound from any one of claims 1-13.